Fabrication, Characterization, and In Vivo Evaluation of Famotidine Loaded Solid Lipid Nanoparticles for Boosting Oral Bioavailability

Table 3

Cumulative percent release of FTD.

S. No	Time (hrs)	Cumulative drug released (%)
		FFSe-1	FFSe-2	FFSe-3	FFSe-4	FFSe-5
1	0	0	0	0	0	0
2	1	11.98	10.23	9.54	9.12	9.02
3	2	24.63	20.57	20.21	16.86	15.23
4	3	37.42	30.55	29.65	24.23	22.54
5	4	47.87	41.34	38.25	32.12	28.61
6	5	58.83	52.12	47.15	39.19	34.54
7	6	67.82	62.11	54.58	45.98	40.84
8	7	76.53	68.98	61.89	52.85	46.97
9	8	83.12	76.34	70.12	59.12	52.87
10	9	88.97	81.89	76.26	65.29	57.98
11	10	93.24	88.12	82.32	70.84	63.74
12	12	99.21	94.12	88.31	78.87	71.94